Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs
Immunovant (Nasdaq: IMVT) has announced an upcoming investor webcast scheduled for Wednesday, March 19, 2025, at 8:00 AM ET. The presentation will focus on revealing results from two significant clinical trials: the Phase 3 study of batoclimab in Myasthenia Gravis (MG) and initial findings from the Phase 2b study in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
The webcast will feature presentations from Pete Salzmann, M.D., MBA, Immunovant's Chief Executive Officer, alongside Matt Gline, Chief Executive Officer of Roivant. Interested participants can access the live webcast through registration, and it will also be available in the News & Events section of Immunovant's website. A replay option will be provided immediately after the event.
Immunovant (Nasdaq: IMVT) ha annunciato un prossimo webcast per investitori programmato per mercoledì 19 marzo 2025, alle 8:00 AM ET. La presentazione si concentrerà sulla rivelazione dei risultati di due significativi studi clinici: lo studio di Fase 3 di batoclimab nella Miastenia Grave (MG) e i risultati iniziali del studio di Fase 2b nella Neuropatia Infiammatoria Cronica Demielinizzante (CIDP).
Il webcast presenterà interventi di Pete Salzmann, M.D., MBA, Amministratore Delegato di Immunovant, insieme a Matt Gline, Amministratore Delegato di Roivant. I partecipanti interessati possono accedere al webcast dal vivo tramite registrazione, e sarà anche disponibile nella sezione Notizie ed Eventi del sito web di Immunovant. Un'opzione di replay sarà fornita immediatamente dopo l'evento.
Immunovant (Nasdaq: IMVT) ha anunciado un próximo webcast para inversores programado para miércoles 19 de marzo de 2025, a las 8:00 AM ET. La presentación se centrará en revelar los resultados de dos ensayos clínicos significativos: el estudio de Fase 3 de batoclimab en Miastenia Gravis (MG) y los hallazgos iniciales del estudio de Fase 2b en Neuropatía Inflamatoria Crónica Desmielinizante (CIDP).
El webcast contará con presentaciones de Pete Salzmann, M.D., MBA, Director Ejecutivo de Immunovant, junto a Matt Gline, Director Ejecutivo de Roivant. Los participantes interesados pueden acceder al webcast en vivo a través de la registración, y también estará disponible en la sección de Noticias y Eventos del sitio web de Immunovant. Se proporcionará una opción de repetición inmediatamente después del evento.
Immunovant (Nasdaq: IMVT)는 2025년 3월 19일 수요일 오전 8:00 ET에 예정된 투자자 웹캐스트를 발표했습니다. 발표는 두 가지 중요한 임상 시험 결과를 공개하는 데 초점을 맞출 것입니다: 중증 근무력증(MG)에서의 batoclimab에 대한 3상 연구와 만성 염증성 탈수초성 다발신경병증(CIDP)에서의 2b상 연구의 초기 결과.
웹캐스트에서는 Pete Salzmann, M.D., MBA, Immunovant의 CEO와 Matt Gline, Roivant의 CEO가 발표할 예정입니다. 관심 있는 참가자는 등록을 통해 실시간 웹캐스트에 접근할 수 있으며, Immunovant 웹사이트의 뉴스 및 이벤트 섹션에서도 이용할 수 있습니다. 이벤트 직후 재생 옵션이 제공됩니다.
Immunovant (Nasdaq: IMVT) a annoncé un prochain webinaire pour investisseurs prévu pour mercredi 19 mars 2025, à 8h00 ET. La présentation se concentrera sur la révélation des résultats de deux essais cliniques significatifs : l'étude de Phase 3 de batoclimab dans la myasthénie grave (MG) et les résultats préliminaires de l'étude de Phase 2b dans la neuropathie démyélinisante inflammatoire chronique (CIDP).
Le webinaire comprendra des présentations de Pete Salzmann, M.D., MBA, PDG d'Immunovant, ainsi que de Matt Gline, PDG de Roivant. Les participants intéressés peuvent accéder au webinaire en direct via une inscription, et il sera également disponible dans la section Actualités et Événements du site Web d'Immunovant. Une option de rediffusion sera fournie immédiatement après l'événement.
Immunovant (Nasdaq: IMVT) hat ein bevorstehendes Investor-Webcast angekündigt, das für Mittwoch, den 19. März 2025, um 8:00 Uhr ET geplant ist. Die Präsentation wird sich auf die Offenlegung der Ergebnisse von zwei bedeutenden klinischen Studien konzentrieren: der Phase-3-Studie zu batoclimab bei Myasthenia Gravis (MG) und den ersten Ergebnissen der Phase-2b-Studie zur chronischen entzündlichen demyelinisierenden Polyneuropathie (CIDP).
Das Webcast wird Präsentationen von Pete Salzmann, M.D., MBA, CEO von Immunovant, und Matt Gline, CEO von Roivant, beinhalten. Interessierte Teilnehmer können über eine Registrierung auf das Live-Webcast zugreifen, das auch im Bereich Nachrichten und Veranstaltungen auf der Website von Immunovant verfügbar sein wird. Eine Wiederholungsoption wird unmittelbar nach der Veranstaltung bereitgestellt.
- None.
- None.
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Wednesday, March 19th at 8:00 a.m. ET to review results from its Phase 3 study of batoclimab in MG and initial results from its Phase 2b study in CIDP.
Pete Salzmann, M.D., MBA, Chief Executive Officer of Immunovant, will be joined by Matt Gline, Chief Executive Officer of Roivant, for the call.
Webcast Details
The company will host a webcast at 8:00 a.m. ET on Wednesday, March 19. Please click here to register for the event. The live webcast will also be available under the News & Events section of Immunovant’s website. A replay of the event and presentation will be available immediately following the event.
About Immunovant, Inc.
Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit immunovant.com.
Contact:
Renee Barnett, MBA
Chief Financial Officer
Immunovant, Inc.
info@immunovant.com
FAQ
When will Immunovant (IMVT) present its batoclimab Phase 3 MG study results?
What clinical trial results will IMVT discuss in the March 19 webcast?
How can investors access the IMVT March 19 webcast?
Who will be presenting at the IMVT investor webcast on March 19?
